
Opinion|Videos|December 13, 2023
Closing Remarks on Bispecific Antibodies
Author(s)Justin LaPorte, PharmD, BCOP
Justin LaPorte, PharmD, BCOP, offers closing remarks following discussion on the administration of bispecific antibodies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
5































